​

Funding Round

Series D - Tarveda Therapeutics

Series D - Tarveda Therapeutics

Investment Firm

Overview

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.

Announced Date

Feb 02, 2017

Funding Type

Series D

Highlights

Location

United States, North America

Social

Investor Lead

Versant Ventures

Versant Ventures

Versant Ventures is a early_stage_venture and late_stage_venture and post_ipo firm.

Participant Investors

5

Investor Name
Participant InvestorNovo Holdings
Participant Investor+ND Capital
Participant InvestorVersant Ventures
Participant InvestorNew Enterprise Associates
Participant InvestorFlagship Pioneering

Round Details and Background

Tarveda Therapeutics raised $30000000 on 2017-02-02 in Series D

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.

Company Funding History

9

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 07, 2015
Series B - Tarveda Therapeutics
4-21.0M
Mar 12, 2014
Venture Round - Tarveda Therapeutics
-1.0M
Dec 24, 2013
Series B - Tarveda Therapeutics
3-21.0M
Jan 06, 2012
Series A - Tarveda Therapeutics
3-2.8M

Recent Activity

There is no recent news or activity for this profile.